 |
|
|
| |
Progress toward HCV microelimination among HIV-positive patients in Taiwan
|
| |
| |
1. Taiwan has committed to achieving HCV elimination by 2025.
2. HCV testing and antiviral treatments are reimbursed by the National Health Insurance.
3. direct-acting antivirals (DAAs) were reimbursed in 2017 .
4. Second-course DAA retreatment for HCV reinfection was implemented in 2021.
CROI 2022 Feb 11-16
Shu-Yuan Ho1, Li-Hsin Su2, Hsin-Yun Sun2, Miao-Hui Huang3, Yu-Shan Huang2, Sung-Hsi Huang4, Yi-Chia Huang4, Kuan-Yin Lin2, Wen-Chun Liu2, Yi-Ching Su2, Sui-Yuan Chang1, Chien-Ching Hung2
Departments of 1Laboratory Medicine, 2Internal Medicine National Taiwan University Hospital, Taiwan, 3Internal Medicine, Hualien Tzu Chi Hospital, Taiwan, 4Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Taiwan
|
| |
|
|
|
|
|
